Physician profile

Jackie W Etheridge

Psychiatric/Mental Health (Nurse Practitioner) · Pineville, LA

NPI 1740515790

$479.18

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$309.68

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $325.86 2021-2023
Lundbeck LLC $48.19 2023 Rexulti
Otsuka America Pharmaceutical, INC. $32.64 2022-2023 Rexulti
Neurocrine Biosciences, INC. $21.29 2023 Ingrezza
Janssen Pharmaceuticals, INC $19.61 2023 Spravato
Alkermes, INC. $16.91 2023 Aristada, Lybalvi
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $14.68 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jackie W Etheridge

$479.18

in general payments reported 2019-2025

Years
2021-2023
Top company
Abbvie INC.

https://glasscript.com/doctor/10632884/jackie-w-etheridge

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.